Home/Pipeline/23-valent Pneumococcal Polysaccharide Vaccine

23-valent Pneumococcal Polysaccharide Vaccine

Pneumococcal Disease Prevention

Phase 1Active

Key Facts

Indication

Pneumococcal Disease Prevention

Phase

Phase 1

Status

Active

Company

A Chinese vaccine developer advancing proprietary subunit and mRNA vaccines, with a lead quadrivalent influenza vaccine in late-stage trials.

Drug	Company	Phase	Status
24-valent Pneumococcal Conjugate Vaccine	CanSino Biologics	Pre-clinical	Active
13-valent Pneumococcal Conjugate Vaccine (PCV13)	Hualan Biological Engineering	Phase III	Active
Pneumococcal Polysaccharide Vaccine (PPV)	Sinovac Biotech	Phase II	Active